Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study

Cancer Immunology, Immunotherapy · Published 2026-08-26 · Journal article · DOI 10.1007/s00262-026-04534-5

Free full text

Authors (14)

Bolun Zhao, Wenjing Tang, Jinyuan Xu, Junfeng Hao, Yu Liu, Weinan Guo, Tao Zhao, Jianhong Zhao, Chunxia Zhao, Qingyi Wei, Tianwen Gao, Guannan Zhu, Chunying Li, Qiong Shi

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Zhao, B., Tang, W., Xu, J., et al. (2026). Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04534-5

Related articles